nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0696	0.218	CbGbCtD
Celecoxib—PTGS2—Etoposide—uterine cancer	0.0607	0.19	CbGbCtD
Celecoxib—CYP2C9—Progesterone—uterine cancer	0.0461	0.145	CbGbCtD
Celecoxib—CYP2D6—Progesterone—uterine cancer	0.0422	0.132	CbGbCtD
Celecoxib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0405	0.127	CbGbCtD
Celecoxib—CYP3A4—Progesterone—uterine cancer	0.0268	0.0841	CbGbCtD
Celecoxib—CYP2D6—Doxorubicin—uterine cancer	0.0129	0.0403	CbGbCtD
Celecoxib—CYP3A4—Etoposide—uterine cancer	0.012	0.0376	CbGbCtD
Celecoxib—CYP3A4—Doxorubicin—uterine cancer	0.00818	0.0257	CbGbCtD
Celecoxib—CA6—exocrine gland—uterine cancer	0.00714	0.0631	CbGeAlD
Celecoxib—PDPK1—myometrium—uterine cancer	0.00654	0.0578	CbGeAlD
Celecoxib—PDPK1—uterine cervix—uterine cancer	0.00509	0.0449	CbGeAlD
Celecoxib—PDPK1—renal system—uterine cancer	0.00476	0.0421	CbGeAlD
Celecoxib—PDPK1—uterus—uterine cancer	0.00424	0.0375	CbGeAlD
Celecoxib—PDPK1—female reproductive system—uterine cancer	0.00381	0.0337	CbGeAlD
Celecoxib—CA5A—female reproductive system—uterine cancer	0.00358	0.0316	CbGeAlD
Celecoxib—PDPK1—female gonad—uterine cancer	0.00347	0.0306	CbGeAlD
Celecoxib—PDPK1—vagina—uterine cancer	0.00345	0.0305	CbGeAlD
Celecoxib—MAPK14—epithelium—uterine cancer	0.00275	0.0242	CbGeAlD
Celecoxib—MAPK14—uterine cervix—uterine cancer	0.00272	0.024	CbGeAlD
Celecoxib—MAPK14—smooth muscle tissue—uterine cancer	0.00265	0.0234	CbGeAlD
Celecoxib—MAPK14—decidua—uterine cancer	0.00259	0.0229	CbGeAlD
Celecoxib—MAPK14—renal system—uterine cancer	0.00255	0.0225	CbGeAlD
Celecoxib—CA2—exocrine gland—uterine cancer	0.00246	0.0217	CbGeAlD
Celecoxib—MAPK14—uterus—uterine cancer	0.00227	0.02	CbGeAlD
Celecoxib—PDPK1—lymph node—uterine cancer	0.00223	0.0197	CbGeAlD
Celecoxib—CA9—female reproductive system—uterine cancer	0.00209	0.0185	CbGeAlD
Celecoxib—PTGS2—artery—uterine cancer	0.00208	0.0184	CbGeAlD
Celecoxib—MAPK14—female reproductive system—uterine cancer	0.00204	0.018	CbGeAlD
Celecoxib—CA12—renal system—uterine cancer	0.00193	0.0171	CbGeAlD
Celecoxib—MAPK14—female gonad—uterine cancer	0.00186	0.0164	CbGeAlD
Celecoxib—MAPK14—vagina—uterine cancer	0.00185	0.0163	CbGeAlD
Celecoxib—CA5B—mammalian vulva—uterine cancer	0.00162	0.0143	CbGeAlD
Celecoxib—CA12—female reproductive system—uterine cancer	0.00155	0.0137	CbGeAlD
Celecoxib—ORM1—endometrium—uterine cancer	0.00148	0.0131	CbGeAlD
Celecoxib—CA5B—female reproductive system—uterine cancer	0.00139	0.0123	CbGeAlD
Celecoxib—ABCC4—renal system—uterine cancer	0.0013	0.0115	CbGeAlD
Celecoxib—CA5B—vagina—uterine cancer	0.00126	0.0111	CbGeAlD
Celecoxib—ORM1—female reproductive system—uterine cancer	0.00123	0.0108	CbGeAlD
Celecoxib—CA4—renal system—uterine cancer	0.0012	0.0106	CbGeAlD
Celecoxib—MAPK14—lymph node—uterine cancer	0.00119	0.0105	CbGeAlD
Celecoxib—ABCC4—uterus—uterine cancer	0.00116	0.0102	CbGeAlD
Celecoxib—CA2—epithelium—uterine cancer	0.00107	0.00944	CbGeAlD
Celecoxib—ABCC4—female reproductive system—uterine cancer	0.00104	0.0092	CbGeAlD
Celecoxib—CA2—smooth muscle tissue—uterine cancer	0.00103	0.0091	CbGeAlD
Celecoxib—CA2—decidua—uterine cancer	0.00101	0.00892	CbGeAlD
Celecoxib—PTGS2—myometrium—uterine cancer	0.00101	0.00888	CbGeAlD
Celecoxib—CA2—renal system—uterine cancer	0.000992	0.00876	CbGeAlD
Celecoxib—CA4—female reproductive system—uterine cancer	0.000958	0.00846	CbGeAlD
Celecoxib—ABCC4—female gonad—uterine cancer	0.000949	0.00838	CbGeAlD
Celecoxib—CA2—mammalian vulva—uterine cancer	0.000928	0.00819	CbGeAlD
Celecoxib—CA4—female gonad—uterine cancer	0.000872	0.0077	CbGeAlD
Celecoxib—CA5B—lymph node—uterine cancer	0.000812	0.00717	CbGeAlD
Celecoxib—CA2—female reproductive system—uterine cancer	0.000795	0.00702	CbGeAlD
Celecoxib—PTGS2—epithelium—uterine cancer	0.00079	0.00697	CbGeAlD
Celecoxib—PTGS2—uterine cervix—uterine cancer	0.000783	0.00691	CbGeAlD
Celecoxib—PTGS2—smooth muscle tissue—uterine cancer	0.000761	0.00672	CbGeAlD
Celecoxib—PTGS2—renal system—uterine cancer	0.000733	0.00647	CbGeAlD
Celecoxib—CA2—female gonad—uterine cancer	0.000723	0.00638	CbGeAlD
Celecoxib—CA2—vagina—uterine cancer	0.000719	0.00635	CbGeAlD
Celecoxib—ORM1—lymph node—uterine cancer	0.000718	0.00634	CbGeAlD
Celecoxib—PTGS2—endometrium—uterine cancer	0.000708	0.00625	CbGeAlD
Celecoxib—CYP2C9—female reproductive system—uterine cancer	0.000672	0.00594	CbGeAlD
Celecoxib—PTGS2—uterus—uterine cancer	0.000653	0.00576	CbGeAlD
Celecoxib—CYP3A4—renal system—uterine cancer	0.00064	0.00565	CbGeAlD
Celecoxib—ALB—lymph node—uterine cancer	0.00063	0.00556	CbGeAlD
Celecoxib—CYP2D6—renal system—uterine cancer	0.00063	0.00556	CbGeAlD
Celecoxib—ABCC4—lymph node—uterine cancer	0.00061	0.00538	CbGeAlD
Celecoxib—PTGS2—female reproductive system—uterine cancer	0.000587	0.00518	CbGeAlD
Celecoxib—CA4—lymph node—uterine cancer	0.000561	0.00495	CbGeAlD
Celecoxib—PTGS2—female gonad—uterine cancer	0.000534	0.00471	CbGeAlD
Celecoxib—PTGS2—vagina—uterine cancer	0.000531	0.00468	CbGeAlD
Celecoxib—CYP3A4—female reproductive system—uterine cancer	0.000513	0.00453	CbGeAlD
Celecoxib—CYP2D6—female reproductive system—uterine cancer	0.000504	0.00445	CbGeAlD
Celecoxib—CA2—lymph node—uterine cancer	0.000465	0.0041	CbGeAlD
Celecoxib—CYP2D6—female gonad—uterine cancer	0.000459	0.00405	CbGeAlD
Celecoxib—PTGS2—lymph node—uterine cancer	0.000343	0.00303	CbGeAlD
Celecoxib—Blood creatinine increased—Doxorubicin—uterine cancer	0.000183	0.00052	CcSEcCtD
Celecoxib—Dysphagia—Epirubicin—uterine cancer	0.000182	0.000518	CcSEcCtD
Celecoxib—Thrombocytopenia—Etoposide—uterine cancer	0.000181	0.000515	CcSEcCtD
Celecoxib—Tachycardia—Etoposide—uterine cancer	0.00018	0.000513	CcSEcCtD
Celecoxib—Eosinophilia—Epirubicin—uterine cancer	0.00018	0.000513	CcSEcCtD
Celecoxib—Liver function test abnormal—Doxorubicin—uterine cancer	0.00018	0.000512	CcSEcCtD
Celecoxib—Skin disorder—Etoposide—uterine cancer	0.000179	0.000511	CcSEcCtD
Celecoxib—Dry skin—Doxorubicin—uterine cancer	0.000179	0.000508	CcSEcCtD
Celecoxib—Hyperhidrosis—Etoposide—uterine cancer	0.000178	0.000508	CcSEcCtD
Celecoxib—Pancreatitis—Epirubicin—uterine cancer	0.000178	0.000508	CcSEcCtD
Celecoxib—Abdominal pain upper—Doxorubicin—uterine cancer	0.000178	0.000507	CcSEcCtD
Celecoxib—Hypokalaemia—Doxorubicin—uterine cancer	0.000177	0.000505	CcSEcCtD
Celecoxib—Angina pectoris—Epirubicin—uterine cancer	0.000177	0.000505	CcSEcCtD
Celecoxib—Breast disorder—Doxorubicin—uterine cancer	0.000176	0.000501	CcSEcCtD
Celecoxib—Anorexia—Etoposide—uterine cancer	0.000176	0.000501	CcSEcCtD
Celecoxib—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000175	0.0005	CcSEcCtD
Celecoxib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000175	0.0005	CcSEcCtD
Celecoxib—Bronchitis—Epirubicin—uterine cancer	0.000175	0.000498	CcSEcCtD
Celecoxib—Diarrhoea—Dactinomycin—uterine cancer	0.000175	0.000497	CcSEcCtD
Celecoxib—Nasopharyngitis—Doxorubicin—uterine cancer	0.000174	0.000496	CcSEcCtD
Celecoxib—Pancytopenia—Epirubicin—uterine cancer	0.000173	0.000492	CcSEcCtD
Celecoxib—Gastritis—Doxorubicin—uterine cancer	0.000172	0.000491	CcSEcCtD
Celecoxib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000172	0.000489	CcSEcCtD
Celecoxib—Dysuria—Epirubicin—uterine cancer	0.00017	0.000485	CcSEcCtD
Celecoxib—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000169	0.000482	CcSEcCtD
Celecoxib—Dysphagia—Doxorubicin—uterine cancer	0.000168	0.000479	CcSEcCtD
Celecoxib—Pollakiuria—Epirubicin—uterine cancer	0.000168	0.000479	CcSEcCtD
Celecoxib—Eosinophilia—Doxorubicin—uterine cancer	0.000167	0.000475	CcSEcCtD
Celecoxib—Photosensitivity reaction—Epirubicin—uterine cancer	0.000166	0.000473	CcSEcCtD
Celecoxib—Paraesthesia—Etoposide—uterine cancer	0.000166	0.000472	CcSEcCtD
Celecoxib—Weight increased—Epirubicin—uterine cancer	0.000166	0.000472	CcSEcCtD
Celecoxib—Pancreatitis—Doxorubicin—uterine cancer	0.000165	0.00047	CcSEcCtD
Celecoxib—Dyspnoea—Etoposide—uterine cancer	0.000165	0.000469	CcSEcCtD
Celecoxib—Hyperglycaemia—Epirubicin—uterine cancer	0.000164	0.000467	CcSEcCtD
Celecoxib—Somnolence—Etoposide—uterine cancer	0.000164	0.000467	CcSEcCtD
Celecoxib—Angina pectoris—Doxorubicin—uterine cancer	0.000164	0.000467	CcSEcCtD
Celecoxib—Pneumonia—Epirubicin—uterine cancer	0.000163	0.000465	CcSEcCtD
Celecoxib—Infestation NOS—Epirubicin—uterine cancer	0.000162	0.000462	CcSEcCtD
Celecoxib—Infestation—Epirubicin—uterine cancer	0.000162	0.000462	CcSEcCtD
Celecoxib—Vomiting—Dactinomycin—uterine cancer	0.000162	0.000462	CcSEcCtD
Celecoxib—Bronchitis—Doxorubicin—uterine cancer	0.000162	0.000461	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000161	0.000458	CcSEcCtD
Celecoxib—Rash—Dactinomycin—uterine cancer	0.000161	0.000458	CcSEcCtD
Celecoxib—Decreased appetite—Etoposide—uterine cancer	0.000161	0.000457	CcSEcCtD
Celecoxib—Pancytopenia—Doxorubicin—uterine cancer	0.00016	0.000455	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000159	0.000454	CcSEcCtD
Celecoxib—Fatigue—Etoposide—uterine cancer	0.000159	0.000453	CcSEcCtD
Celecoxib—Neuropathy peripheral—Epirubicin—uterine cancer	0.000159	0.000453	CcSEcCtD
Celecoxib—Jaundice—Epirubicin—uterine cancer	0.000158	0.00045	CcSEcCtD
Celecoxib—Stomatitis—Epirubicin—uterine cancer	0.000158	0.00045	CcSEcCtD
Celecoxib—Constipation—Etoposide—uterine cancer	0.000158	0.00045	CcSEcCtD
Celecoxib—Conjunctivitis—Epirubicin—uterine cancer	0.000158	0.000449	CcSEcCtD
Celecoxib—Urinary tract infection—Epirubicin—uterine cancer	0.000158	0.000449	CcSEcCtD
Celecoxib—Dysuria—Doxorubicin—uterine cancer	0.000157	0.000448	CcSEcCtD
Celecoxib—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000157	0.000446	CcSEcCtD
Celecoxib—Pollakiuria—Doxorubicin—uterine cancer	0.000156	0.000443	CcSEcCtD
Celecoxib—Haematuria—Epirubicin—uterine cancer	0.000155	0.000441	CcSEcCtD
Celecoxib—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000154	0.000438	CcSEcCtD
Celecoxib—Hepatobiliary disease—Epirubicin—uterine cancer	0.000153	0.000437	CcSEcCtD
Celecoxib—Weight increased—Doxorubicin—uterine cancer	0.000153	0.000436	CcSEcCtD
Celecoxib—Epistaxis—Epirubicin—uterine cancer	0.000153	0.000436	CcSEcCtD
Celecoxib—Sinusitis—Epirubicin—uterine cancer	0.000152	0.000433	CcSEcCtD
Celecoxib—Feeling abnormal—Etoposide—uterine cancer	0.000152	0.000433	CcSEcCtD
Celecoxib—Hyperglycaemia—Doxorubicin—uterine cancer	0.000152	0.000433	CcSEcCtD
Celecoxib—Nausea—Dactinomycin—uterine cancer	0.000152	0.000431	CcSEcCtD
Celecoxib—Agranulocytosis—Epirubicin—uterine cancer	0.000151	0.000431	CcSEcCtD
Celecoxib—Pneumonia—Doxorubicin—uterine cancer	0.000151	0.00043	CcSEcCtD
Celecoxib—Gastrointestinal pain—Etoposide—uterine cancer	0.000151	0.00043	CcSEcCtD
Celecoxib—Infestation—Doxorubicin—uterine cancer	0.00015	0.000428	CcSEcCtD
Celecoxib—Infestation NOS—Doxorubicin—uterine cancer	0.00015	0.000428	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000149	0.000424	CcSEcCtD
Celecoxib—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000147	0.000419	CcSEcCtD
Celecoxib—Urticaria—Etoposide—uterine cancer	0.000147	0.000418	CcSEcCtD
Celecoxib—Haemoglobin—Epirubicin—uterine cancer	0.000146	0.000417	CcSEcCtD
Celecoxib—Stomatitis—Doxorubicin—uterine cancer	0.000146	0.000417	CcSEcCtD
Celecoxib—Jaundice—Doxorubicin—uterine cancer	0.000146	0.000417	CcSEcCtD
Celecoxib—Rhinitis—Epirubicin—uterine cancer	0.000146	0.000416	CcSEcCtD
Celecoxib—Abdominal pain—Etoposide—uterine cancer	0.000146	0.000416	CcSEcCtD
Celecoxib—Body temperature increased—Etoposide—uterine cancer	0.000146	0.000416	CcSEcCtD
Celecoxib—Urinary tract infection—Doxorubicin—uterine cancer	0.000146	0.000416	CcSEcCtD
Celecoxib—Conjunctivitis—Doxorubicin—uterine cancer	0.000146	0.000416	CcSEcCtD
Celecoxib—Hepatitis—Epirubicin—uterine cancer	0.000146	0.000415	CcSEcCtD
Celecoxib—Haemorrhage—Epirubicin—uterine cancer	0.000146	0.000415	CcSEcCtD
Celecoxib—Hypoaesthesia—Epirubicin—uterine cancer	0.000145	0.000413	CcSEcCtD
Celecoxib—Pharyngitis—Epirubicin—uterine cancer	0.000145	0.000412	CcSEcCtD
Celecoxib—Urinary tract disorder—Epirubicin—uterine cancer	0.000144	0.00041	CcSEcCtD
Celecoxib—Oedema peripheral—Epirubicin—uterine cancer	0.000144	0.000409	CcSEcCtD
Celecoxib—Haematuria—Doxorubicin—uterine cancer	0.000143	0.000408	CcSEcCtD
Celecoxib—Connective tissue disorder—Epirubicin—uterine cancer	0.000143	0.000408	CcSEcCtD
Celecoxib—Urethral disorder—Epirubicin—uterine cancer	0.000143	0.000407	CcSEcCtD
Celecoxib—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000142	0.000404	CcSEcCtD
Celecoxib—Epistaxis—Doxorubicin—uterine cancer	0.000142	0.000403	CcSEcCtD
Celecoxib—Sinusitis—Doxorubicin—uterine cancer	0.000141	0.000401	CcSEcCtD
Celecoxib—Agranulocytosis—Doxorubicin—uterine cancer	0.00014	0.000399	CcSEcCtD
Celecoxib—Erythema multiforme—Epirubicin—uterine cancer	0.000138	0.000392	CcSEcCtD
Celecoxib—Eye disorder—Epirubicin—uterine cancer	0.000136	0.000388	CcSEcCtD
Celecoxib—Hypersensitivity—Etoposide—uterine cancer	0.000136	0.000387	CcSEcCtD
Celecoxib—Tinnitus—Epirubicin—uterine cancer	0.000136	0.000387	CcSEcCtD
Celecoxib—Haemoglobin—Doxorubicin—uterine cancer	0.000135	0.000386	CcSEcCtD
Celecoxib—Cardiac disorder—Epirubicin—uterine cancer	0.000135	0.000385	CcSEcCtD
Celecoxib—Flushing—Epirubicin—uterine cancer	0.000135	0.000385	CcSEcCtD
Celecoxib—Rhinitis—Doxorubicin—uterine cancer	0.000135	0.000385	CcSEcCtD
Celecoxib—Hepatitis—Doxorubicin—uterine cancer	0.000135	0.000384	CcSEcCtD
Celecoxib—Haemorrhage—Doxorubicin—uterine cancer	0.000135	0.000384	CcSEcCtD
Celecoxib—Hypoaesthesia—Doxorubicin—uterine cancer	0.000134	0.000382	CcSEcCtD
Celecoxib—Pharyngitis—Doxorubicin—uterine cancer	0.000134	0.000381	CcSEcCtD
Celecoxib—Urinary tract disorder—Doxorubicin—uterine cancer	0.000133	0.000379	CcSEcCtD
Celecoxib—Oedema peripheral—Doxorubicin—uterine cancer	0.000133	0.000378	CcSEcCtD
Celecoxib—Asthenia—Etoposide—uterine cancer	0.000132	0.000377	CcSEcCtD
Celecoxib—Connective tissue disorder—Doxorubicin—uterine cancer	0.000132	0.000377	CcSEcCtD
Celecoxib—Angiopathy—Epirubicin—uterine cancer	0.000132	0.000376	CcSEcCtD
Celecoxib—Urethral disorder—Doxorubicin—uterine cancer	0.000132	0.000376	CcSEcCtD
Celecoxib—Immune system disorder—Epirubicin—uterine cancer	0.000132	0.000375	CcSEcCtD
Celecoxib—Mediastinal disorder—Epirubicin—uterine cancer	0.000131	0.000374	CcSEcCtD
Celecoxib—Pruritus—Etoposide—uterine cancer	0.000131	0.000372	CcSEcCtD
Celecoxib—Arrhythmia—Epirubicin—uterine cancer	0.00013	0.000371	CcSEcCtD
Celecoxib—Alopecia—Epirubicin—uterine cancer	0.000129	0.000367	CcSEcCtD
Celecoxib—Mental disorder—Epirubicin—uterine cancer	0.000128	0.000363	CcSEcCtD
Celecoxib—Erythema multiforme—Doxorubicin—uterine cancer	0.000127	0.000363	CcSEcCtD
Celecoxib—Diarrhoea—Etoposide—uterine cancer	0.000126	0.00036	CcSEcCtD
Celecoxib—Eye disorder—Doxorubicin—uterine cancer	0.000126	0.000359	CcSEcCtD
Celecoxib—Tinnitus—Doxorubicin—uterine cancer	0.000126	0.000358	CcSEcCtD
Celecoxib—Flushing—Doxorubicin—uterine cancer	0.000125	0.000356	CcSEcCtD
Celecoxib—Cardiac disorder—Doxorubicin—uterine cancer	0.000125	0.000356	CcSEcCtD
Celecoxib—Flatulence—Epirubicin—uterine cancer	0.000125	0.000356	CcSEcCtD
Celecoxib—Tension—Epirubicin—uterine cancer	0.000124	0.000354	CcSEcCtD
Celecoxib—Dysgeusia—Epirubicin—uterine cancer	0.000124	0.000354	CcSEcCtD
Celecoxib—Nervousness—Epirubicin—uterine cancer	0.000123	0.000351	CcSEcCtD
Celecoxib—Back pain—Epirubicin—uterine cancer	0.000123	0.000349	CcSEcCtD
Celecoxib—Angiopathy—Doxorubicin—uterine cancer	0.000122	0.000348	CcSEcCtD
Celecoxib—Dizziness—Etoposide—uterine cancer	0.000122	0.000348	CcSEcCtD
Celecoxib—Muscle spasms—Epirubicin—uterine cancer	0.000122	0.000347	CcSEcCtD
Celecoxib—Immune system disorder—Doxorubicin—uterine cancer	0.000122	0.000347	CcSEcCtD
Celecoxib—Mediastinal disorder—Doxorubicin—uterine cancer	0.000121	0.000346	CcSEcCtD
Celecoxib—Arrhythmia—Doxorubicin—uterine cancer	0.00012	0.000343	CcSEcCtD
Celecoxib—Vision blurred—Epirubicin—uterine cancer	0.00012	0.00034	CcSEcCtD
Celecoxib—Alopecia—Doxorubicin—uterine cancer	0.000119	0.000339	CcSEcCtD
Celecoxib—Mental disorder—Doxorubicin—uterine cancer	0.000118	0.000336	CcSEcCtD
Celecoxib—Vomiting—Etoposide—uterine cancer	0.000117	0.000334	CcSEcCtD
Celecoxib—Anaemia—Epirubicin—uterine cancer	0.000117	0.000334	CcSEcCtD
Celecoxib—Rash—Etoposide—uterine cancer	0.000116	0.000331	CcSEcCtD
Celecoxib—Dermatitis—Etoposide—uterine cancer	0.000116	0.000331	CcSEcCtD
Celecoxib—Headache—Etoposide—uterine cancer	0.000116	0.000329	CcSEcCtD
Celecoxib—Flatulence—Doxorubicin—uterine cancer	0.000116	0.000329	CcSEcCtD
Celecoxib—Tension—Doxorubicin—uterine cancer	0.000115	0.000328	CcSEcCtD
Celecoxib—Dysgeusia—Doxorubicin—uterine cancer	0.000115	0.000327	CcSEcCtD
Celecoxib—Nervousness—Doxorubicin—uterine cancer	0.000114	0.000324	CcSEcCtD
Celecoxib—Vertigo—Epirubicin—uterine cancer	0.000114	0.000324	CcSEcCtD
Celecoxib—Syncope—Epirubicin—uterine cancer	0.000114	0.000324	CcSEcCtD
Celecoxib—Leukopenia—Epirubicin—uterine cancer	0.000114	0.000323	CcSEcCtD
Celecoxib—Back pain—Doxorubicin—uterine cancer	0.000114	0.000323	CcSEcCtD
Celecoxib—Muscle spasms—Doxorubicin—uterine cancer	0.000113	0.000321	CcSEcCtD
Celecoxib—Palpitations—Epirubicin—uterine cancer	0.000112	0.000319	CcSEcCtD
Celecoxib—Loss of consciousness—Epirubicin—uterine cancer	0.000111	0.000317	CcSEcCtD
Celecoxib—Cough—Epirubicin—uterine cancer	0.000111	0.000315	CcSEcCtD
Celecoxib—Vision blurred—Doxorubicin—uterine cancer	0.000111	0.000315	CcSEcCtD
Celecoxib—Nausea—Etoposide—uterine cancer	0.00011	0.000312	CcSEcCtD
Celecoxib—Hypertension—Epirubicin—uterine cancer	0.000109	0.000312	CcSEcCtD
Celecoxib—Anaemia—Doxorubicin—uterine cancer	0.000108	0.000309	CcSEcCtD
Celecoxib—Myalgia—Epirubicin—uterine cancer	0.000108	0.000307	CcSEcCtD
Celecoxib—Chest pain—Epirubicin—uterine cancer	0.000108	0.000307	CcSEcCtD
Celecoxib—Arthralgia—Epirubicin—uterine cancer	0.000108	0.000307	CcSEcCtD
Celecoxib—Anxiety—Epirubicin—uterine cancer	0.000108	0.000306	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000107	0.000305	CcSEcCtD
Celecoxib—Dry mouth—Epirubicin—uterine cancer	0.000106	0.000301	CcSEcCtD
Celecoxib—Vertigo—Doxorubicin—uterine cancer	0.000105	0.0003	CcSEcCtD
Celecoxib—Syncope—Doxorubicin—uterine cancer	0.000105	0.0003	CcSEcCtD
Celecoxib—Leukopenia—Doxorubicin—uterine cancer	0.000105	0.000299	CcSEcCtD
Celecoxib—Confusional state—Epirubicin—uterine cancer	0.000104	0.000297	CcSEcCtD
Celecoxib—Palpitations—Doxorubicin—uterine cancer	0.000104	0.000295	CcSEcCtD
Celecoxib—Oedema—Epirubicin—uterine cancer	0.000103	0.000295	CcSEcCtD
Celecoxib—Anaphylactic shock—Epirubicin—uterine cancer	0.000103	0.000295	CcSEcCtD
Celecoxib—Loss of consciousness—Doxorubicin—uterine cancer	0.000103	0.000294	CcSEcCtD
Celecoxib—Infection—Epirubicin—uterine cancer	0.000103	0.000293	CcSEcCtD
Celecoxib—Cough—Doxorubicin—uterine cancer	0.000102	0.000292	CcSEcCtD
Celecoxib—Shock—Epirubicin—uterine cancer	0.000102	0.00029	CcSEcCtD
Celecoxib—Nervous system disorder—Epirubicin—uterine cancer	0.000101	0.000289	CcSEcCtD
Celecoxib—Thrombocytopenia—Epirubicin—uterine cancer	0.000101	0.000289	CcSEcCtD
Celecoxib—Hypertension—Doxorubicin—uterine cancer	0.000101	0.000288	CcSEcCtD
Celecoxib—Tachycardia—Epirubicin—uterine cancer	0.000101	0.000288	CcSEcCtD
Celecoxib—Skin disorder—Epirubicin—uterine cancer	0.000101	0.000286	CcSEcCtD
Celecoxib—Hyperhidrosis—Epirubicin—uterine cancer	0.0001	0.000285	CcSEcCtD
Celecoxib—Arthralgia—Doxorubicin—uterine cancer	9.99e-05	0.000284	CcSEcCtD
Celecoxib—Chest pain—Doxorubicin—uterine cancer	9.99e-05	0.000284	CcSEcCtD
Celecoxib—Myalgia—Doxorubicin—uterine cancer	9.99e-05	0.000284	CcSEcCtD
Celecoxib—Anxiety—Doxorubicin—uterine cancer	9.96e-05	0.000283	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	9.92e-05	0.000282	CcSEcCtD
Celecoxib—Anorexia—Epirubicin—uterine cancer	9.87e-05	0.000281	CcSEcCtD
Celecoxib—Dry mouth—Doxorubicin—uterine cancer	9.77e-05	0.000278	CcSEcCtD
Celecoxib—Confusional state—Doxorubicin—uterine cancer	9.66e-05	0.000275	CcSEcCtD
Celecoxib—Anaphylactic shock—Doxorubicin—uterine cancer	9.58e-05	0.000273	CcSEcCtD
Celecoxib—Oedema—Doxorubicin—uterine cancer	9.58e-05	0.000273	CcSEcCtD
Celecoxib—Infection—Doxorubicin—uterine cancer	9.51e-05	0.000271	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Epirubicin—uterine cancer	9.43e-05	0.000268	CcSEcCtD
Celecoxib—Shock—Doxorubicin—uterine cancer	9.42e-05	0.000268	CcSEcCtD
Celecoxib—Nervous system disorder—Doxorubicin—uterine cancer	9.39e-05	0.000267	CcSEcCtD
Celecoxib—Thrombocytopenia—Doxorubicin—uterine cancer	9.38e-05	0.000267	CcSEcCtD
Celecoxib—Insomnia—Epirubicin—uterine cancer	9.36e-05	0.000267	CcSEcCtD
Celecoxib—Tachycardia—Doxorubicin—uterine cancer	9.35e-05	0.000266	CcSEcCtD
Celecoxib—Skin disorder—Doxorubicin—uterine cancer	9.3e-05	0.000265	CcSEcCtD
Celecoxib—Paraesthesia—Epirubicin—uterine cancer	9.29e-05	0.000265	CcSEcCtD
Celecoxib—Hyperhidrosis—Doxorubicin—uterine cancer	9.26e-05	0.000264	CcSEcCtD
Celecoxib—Dyspnoea—Epirubicin—uterine cancer	9.23e-05	0.000263	CcSEcCtD
Celecoxib—Somnolence—Epirubicin—uterine cancer	9.2e-05	0.000262	CcSEcCtD
Celecoxib—Anorexia—Doxorubicin—uterine cancer	9.13e-05	0.00026	CcSEcCtD
Celecoxib—Dyspepsia—Epirubicin—uterine cancer	9.11e-05	0.000259	CcSEcCtD
Celecoxib—Decreased appetite—Epirubicin—uterine cancer	9e-05	0.000256	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Epirubicin—uterine cancer	8.94e-05	0.000254	CcSEcCtD
Celecoxib—Fatigue—Epirubicin—uterine cancer	8.92e-05	0.000254	CcSEcCtD
Celecoxib—Constipation—Epirubicin—uterine cancer	8.85e-05	0.000252	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	8.72e-05	0.000248	CcSEcCtD
Celecoxib—Insomnia—Doxorubicin—uterine cancer	8.66e-05	0.000247	CcSEcCtD
Celecoxib—Paraesthesia—Doxorubicin—uterine cancer	8.6e-05	0.000245	CcSEcCtD
Celecoxib—Dyspnoea—Doxorubicin—uterine cancer	8.54e-05	0.000243	CcSEcCtD
Celecoxib—Feeling abnormal—Epirubicin—uterine cancer	8.53e-05	0.000243	CcSEcCtD
Celecoxib—Somnolence—Doxorubicin—uterine cancer	8.51e-05	0.000242	CcSEcCtD
Celecoxib—Gastrointestinal pain—Epirubicin—uterine cancer	8.46e-05	0.000241	CcSEcCtD
Celecoxib—Dyspepsia—Doxorubicin—uterine cancer	8.43e-05	0.00024	CcSEcCtD
Celecoxib—Decreased appetite—Doxorubicin—uterine cancer	8.32e-05	0.000237	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Doxorubicin—uterine cancer	8.27e-05	0.000235	CcSEcCtD
Celecoxib—Fatigue—Doxorubicin—uterine cancer	8.26e-05	0.000235	CcSEcCtD
Celecoxib—Urticaria—Epirubicin—uterine cancer	8.22e-05	0.000234	CcSEcCtD
Celecoxib—Constipation—Doxorubicin—uterine cancer	8.19e-05	0.000233	CcSEcCtD
Celecoxib—Abdominal pain—Epirubicin—uterine cancer	8.18e-05	0.000233	CcSEcCtD
Celecoxib—Body temperature increased—Epirubicin—uterine cancer	8.18e-05	0.000233	CcSEcCtD
Celecoxib—Feeling abnormal—Doxorubicin—uterine cancer	7.89e-05	0.000225	CcSEcCtD
Celecoxib—Gastrointestinal pain—Doxorubicin—uterine cancer	7.83e-05	0.000223	CcSEcCtD
Celecoxib—Hypersensitivity—Epirubicin—uterine cancer	7.63e-05	0.000217	CcSEcCtD
Celecoxib—Urticaria—Doxorubicin—uterine cancer	7.61e-05	0.000217	CcSEcCtD
Celecoxib—Abdominal pain—Doxorubicin—uterine cancer	7.57e-05	0.000216	CcSEcCtD
Celecoxib—Body temperature increased—Doxorubicin—uterine cancer	7.57e-05	0.000216	CcSEcCtD
Celecoxib—Asthenia—Epirubicin—uterine cancer	7.43e-05	0.000211	CcSEcCtD
Celecoxib—Pruritus—Epirubicin—uterine cancer	7.32e-05	0.000208	CcSEcCtD
Celecoxib—Diarrhoea—Epirubicin—uterine cancer	7.08e-05	0.000202	CcSEcCtD
Celecoxib—Hypersensitivity—Doxorubicin—uterine cancer	7.06e-05	0.000201	CcSEcCtD
Celecoxib—Asthenia—Doxorubicin—uterine cancer	6.87e-05	0.000196	CcSEcCtD
Celecoxib—Dizziness—Epirubicin—uterine cancer	6.84e-05	0.000195	CcSEcCtD
Celecoxib—Pruritus—Doxorubicin—uterine cancer	6.78e-05	0.000193	CcSEcCtD
Celecoxib—Vomiting—Epirubicin—uterine cancer	6.58e-05	0.000187	CcSEcCtD
Celecoxib—Diarrhoea—Doxorubicin—uterine cancer	6.55e-05	0.000187	CcSEcCtD
Celecoxib—Rash—Epirubicin—uterine cancer	6.53e-05	0.000186	CcSEcCtD
Celecoxib—Dermatitis—Epirubicin—uterine cancer	6.52e-05	0.000186	CcSEcCtD
Celecoxib—Headache—Epirubicin—uterine cancer	6.48e-05	0.000185	CcSEcCtD
Celecoxib—Dizziness—Doxorubicin—uterine cancer	6.33e-05	0.00018	CcSEcCtD
Celecoxib—Nausea—Epirubicin—uterine cancer	6.15e-05	0.000175	CcSEcCtD
Celecoxib—Vomiting—Doxorubicin—uterine cancer	6.09e-05	0.000173	CcSEcCtD
Celecoxib—Rash—Doxorubicin—uterine cancer	6.04e-05	0.000172	CcSEcCtD
Celecoxib—Dermatitis—Doxorubicin—uterine cancer	6.03e-05	0.000172	CcSEcCtD
Celecoxib—Headache—Doxorubicin—uterine cancer	6e-05	0.000171	CcSEcCtD
Celecoxib—Nausea—Doxorubicin—uterine cancer	5.69e-05	0.000162	CcSEcCtD
Celecoxib—PDPK1—Signaling Pathways—ESR1—uterine cancer	3.07e-05	0.000142	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—AKR1C3—uterine cancer	3.06e-05	0.000141	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CTNNB1—uterine cancer	3.05e-05	0.000141	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—AKR1C1—uterine cancer	3.04e-05	0.00014	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—VEGFA—uterine cancer	3.04e-05	0.00014	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—HRAS—uterine cancer	3.03e-05	0.00014	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—SMAD3—uterine cancer	3e-05	0.000139	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—NRAS—uterine cancer	3e-05	0.000138	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PGR—uterine cancer	2.99e-05	0.000138	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CDKN1B—uterine cancer	2.98e-05	0.000138	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—PTEN—uterine cancer	2.97e-05	0.000137	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—AKT1—uterine cancer	2.94e-05	0.000136	CbGpPWpGaD
Celecoxib—CA12—Metabolism—EP300—uterine cancer	2.93e-05	0.000135	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—NRAS—uterine cancer	2.9e-05	0.000134	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	2.89e-05	0.000134	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—FGFR2—uterine cancer	2.88e-05	0.000133	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CDKN1B—uterine cancer	2.88e-05	0.000133	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—EP300—uterine cancer	2.86e-05	0.000132	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—YWHAE—uterine cancer	2.85e-05	0.000132	CbGpPWpGaD
Celecoxib—MAPK14—Metabolism of RNA—AKT1—uterine cancer	2.84e-05	0.000131	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—EP300—uterine cancer	2.83e-05	0.000131	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—AKT1—uterine cancer	2.82e-05	0.00013	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CTNNB1—uterine cancer	2.81e-05	0.00013	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—EP300—uterine cancer	2.81e-05	0.00013	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	2.8e-05	0.000129	CbGpPWpGaD
Celecoxib—PTGS2—Disease—AKR1C3—uterine cancer	2.79e-05	0.000129	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—STAR—uterine cancer	2.77e-05	0.000128	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—AKR1B1—uterine cancer	2.77e-05	0.000128	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—AKR1B1—uterine cancer	2.74e-05	0.000127	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—STAR—uterine cancer	2.74e-05	0.000127	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PTEN—uterine cancer	2.74e-05	0.000127	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FBXW7—uterine cancer	2.73e-05	0.000126	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HMGA1—uterine cancer	2.72e-05	0.000126	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CTNNB1—uterine cancer	2.72e-05	0.000126	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.71e-05	0.000125	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—RRM2—uterine cancer	2.71e-05	0.000125	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—VEGFA—uterine cancer	2.71e-05	0.000125	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCL2—uterine cancer	2.7e-05	0.000125	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—AKT1—uterine cancer	2.68e-05	0.000124	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—NRAS—uterine cancer	2.68e-05	0.000124	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	2.67e-05	0.000123	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—VEGFA—uterine cancer	2.66e-05	0.000123	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—PTEN—uterine cancer	2.65e-05	0.000122	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—NRAS—uterine cancer	2.65e-05	0.000122	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—DCN—uterine cancer	2.63e-05	0.000121	CbGpPWpGaD
Celecoxib—ALB—Metabolism—POLD1—uterine cancer	2.63e-05	0.000121	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—NRAS—uterine cancer	2.63e-05	0.000121	CbGpPWpGaD
Celecoxib—PDPK1—Disease—EP300—uterine cancer	2.61e-05	0.000121	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—KRAS—uterine cancer	2.58e-05	0.000119	CbGpPWpGaD
Celecoxib—CA14—Metabolism—PIK3CA—uterine cancer	2.57e-05	0.000119	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—EP300—uterine cancer	2.53e-05	0.000117	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—PIK3CA—uterine cancer	2.53e-05	0.000117	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—PIK3CA—uterine cancer	2.5e-05	0.000116	CbGpPWpGaD
Celecoxib—CA6—Metabolism—PIK3CA—uterine cancer	2.5e-05	0.000116	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SRD5A2—uterine cancer	2.5e-05	0.000116	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NDUFB11—uterine cancer	2.5e-05	0.000116	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—KRAS—uterine cancer	2.5e-05	0.000115	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FBXW7—uterine cancer	2.49e-05	0.000115	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CYP11A1—uterine cancer	2.48e-05	0.000114	CbGpPWpGaD
Celecoxib—ALB—Metabolism—AKR1C1—uterine cancer	2.46e-05	0.000114	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—ESR1—uterine cancer	2.45e-05	0.000113	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PTEN—uterine cancer	2.45e-05	0.000113	CbGpPWpGaD
Celecoxib—PDPK1—Disease—NRAS—uterine cancer	2.45e-05	0.000113	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—STK11—uterine cancer	2.39e-05	0.00011	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—PIK3CA—uterine cancer	2.37e-05	0.00011	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—NRAS—uterine cancer	2.36e-05	0.000109	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	2.36e-05	0.000109	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PTEN—uterine cancer	2.35e-05	0.000108	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—AKR1C3—uterine cancer	2.34e-05	0.000108	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—PIK3CA—uterine cancer	2.34e-05	0.000108	CbGpPWpGaD
Celecoxib—CA4—Metabolism—EP300—uterine cancer	2.33e-05	0.000108	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—KRAS—uterine cancer	2.3e-05	0.000106	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TP53—uterine cancer	2.29e-05	0.000106	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—PIK3CA—uterine cancer	2.29e-05	0.000106	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—KRAS—uterine cancer	2.28e-05	0.000105	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—KRAS—uterine cancer	2.26e-05	0.000104	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—ERBB2—uterine cancer	2.25e-05	0.000104	CbGpPWpGaD
Celecoxib—CA2—Metabolism—EP300—uterine cancer	2.24e-05	0.000103	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SOCS3—uterine cancer	2.23e-05	0.000103	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—HRAS—uterine cancer	2.19e-05	0.000101	CbGpPWpGaD
Celecoxib—ALB—Metabolism—RRM2—uterine cancer	2.19e-05	0.000101	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—POLD1—uterine cancer	2.17e-05	0.0001	CbGpPWpGaD
Celecoxib—CA12—Metabolism—PIK3CA—uterine cancer	2.17e-05	0.0001	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—POLD1—uterine cancer	2.15e-05	9.94e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDH1—uterine cancer	2.15e-05	9.9e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN2B—uterine cancer	2.14e-05	9.88e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CXCL8—uterine cancer	2.14e-05	9.86e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—DCN—uterine cancer	2.13e-05	9.83e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—HRAS—uterine cancer	2.12e-05	9.8e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—KRAS—uterine cancer	2.11e-05	9.72e-05	CbGpPWpGaD
Celecoxib—CA14—Metabolism—AKT1—uterine cancer	2.1e-05	9.69e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—PIK3CA—uterine cancer	2.1e-05	9.67e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CDKN1B—uterine cancer	2.09e-05	9.63e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	2.08e-05	9.61e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IGF1R—uterine cancer	2.08e-05	9.59e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—PIK3CA—uterine cancer	2.08e-05	9.59e-05	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—AKT1—uterine cancer	2.06e-05	9.52e-05	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—AKT1—uterine cancer	2.05e-05	9.44e-05	CbGpPWpGaD
Celecoxib—CA6—Metabolism—AKT1—uterine cancer	2.05e-05	9.44e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—KRAS—uterine cancer	2.03e-05	9.39e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—AKR1C1—uterine cancer	2.03e-05	9.38e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—AKR1C1—uterine cancer	2.01e-05	9.3e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TP53—uterine cancer	2.01e-05	9.27e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP11A1—uterine cancer	2.01e-05	9.26e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTEN—uterine cancer	1.98e-05	9.13e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CTNNB1—uterine cancer	1.97e-05	9.1e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—HRAS—uterine cancer	1.96e-05	9.04e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SMAD3—uterine cancer	1.95e-05	9.02e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN2B—uterine cancer	1.95e-05	9.01e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HRAS—uterine cancer	1.94e-05	8.95e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—AKT1—uterine cancer	1.94e-05	8.95e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PIK3CA—uterine cancer	1.93e-05	8.93e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—HRAS—uterine cancer	1.92e-05	8.87e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PTEN—uterine cancer	1.92e-05	8.87e-05	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—AKT1—uterine cancer	1.91e-05	8.82e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—AKR1C3—uterine cancer	1.89e-05	8.74e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—EP300—uterine cancer	1.89e-05	8.71e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—AKT1—uterine cancer	1.87e-05	8.65e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—PIK3CA—uterine cancer	1.87e-05	8.63e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FGFR2—uterine cancer	1.86e-05	8.6e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—EP300—uterine cancer	1.83e-05	8.46e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—STK11—uterine cancer	1.82e-05	8.42e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CYP19A1—uterine cancer	1.82e-05	8.42e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—RRM2—uterine cancer	1.81e-05	8.36e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ERBB2—uterine cancer	1.81e-05	8.36e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.81e-05	8.35e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—STAR—uterine cancer	1.81e-05	8.35e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—RRM2—uterine cancer	1.79e-05	8.29e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—HRAS—uterine cancer	1.79e-05	8.26e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SMAD3—uterine cancer	1.78e-05	8.23e-05	CbGpPWpGaD
Celecoxib—CA12—Metabolism—AKT1—uterine cancer	1.77e-05	8.17e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—DCN—uterine cancer	1.76e-05	8.11e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—DCN—uterine cancer	1.74e-05	8.04e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—VEGFA—uterine cancer	1.73e-05	8.01e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HRAS—uterine cancer	1.73e-05	7.99e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—AKT1—uterine cancer	1.73e-05	7.98e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PIK3CA—uterine cancer	1.73e-05	7.97e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—NRAS—uterine cancer	1.71e-05	7.91e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.71e-05	7.9e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—AKT1—uterine cancer	1.71e-05	7.9e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	1.7e-05	7.85e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FGFR2—uterine cancer	1.7e-05	7.85e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—AKT1—uterine cancer	1.7e-05	7.83e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDKN1B—uterine cancer	1.68e-05	7.74e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.66e-05	7.65e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PIK3CA—uterine cancer	1.66e-05	7.64e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP11A1—uterine cancer	1.64e-05	7.58e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MTHFR—uterine cancer	1.64e-05	7.56e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.63e-05	7.54e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—ESR1—uterine cancer	1.59e-05	7.36e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CTNNB1—uterine cancer	1.58e-05	7.31e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—AKT1—uterine cancer	1.58e-05	7.3e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.56e-05	7.22e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.55e-05	7.16e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PTEN—uterine cancer	1.54e-05	7.13e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—AKT1—uterine cancer	1.53e-05	7.05e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—STK11—uterine cancer	1.48e-05	6.81e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP19A1—uterine cancer	1.48e-05	6.81e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KRAS—uterine cancer	1.47e-05	6.81e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EP300—uterine cancer	1.47e-05	6.8e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—EP300—uterine cancer	1.45e-05	6.7e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—POLD1—uterine cancer	1.42e-05	6.56e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—AKT1—uterine cancer	1.41e-05	6.51e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCL2—uterine cancer	1.4e-05	6.48e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PIK3CA—uterine cancer	1.4e-05	6.44e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.38e-05	6.39e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—NRAS—uterine cancer	1.38e-05	6.36e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—VEGFA—uterine cancer	1.37e-05	6.34e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—MTHFR—uterine cancer	1.37e-05	6.33e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—NRAS—uterine cancer	1.36e-05	6.27e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PIK3CA—uterine cancer	1.35e-05	6.25e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—AKT1—uterine cancer	1.35e-05	6.24e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.33e-05	6.13e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.32e-05	6.1e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—uterine cancer	1.31e-05	6.05e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—HRAS—uterine cancer	1.25e-05	5.79e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—STK11—uterine cancer	1.22e-05	5.62e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP19A1—uterine cancer	1.22e-05	5.62e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.21e-05	5.58e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—STK11—uterine cancer	1.21e-05	5.58e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.21e-05	5.58e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KRAS—uterine cancer	1.19e-05	5.47e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—RRM2—uterine cancer	1.18e-05	5.47e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—ERBB2—uterine cancer	1.17e-05	5.4e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—KRAS—uterine cancer	1.17e-05	5.39e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—DCN—uterine cancer	1.15e-05	5.31e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—AKT1—uterine cancer	1.14e-05	5.26e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.13e-05	5.23e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CXCL8—uterine cancer	1.11e-05	5.12e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—MTHFR—uterine cancer	1.11e-05	5.12e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—AKT1—uterine cancer	1.11e-05	5.11e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CA—uterine cancer	1.09e-05	5.03e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN1B—uterine cancer	1.08e-05	5e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.08e-05	5e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.08e-05	4.99e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CA—uterine cancer	1.07e-05	4.96e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ERBB2—uterine cancer	1.07e-05	4.93e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—uterine cancer	1.04e-05	4.79e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CTNNB1—uterine cancer	1.02e-05	4.73e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.02e-05	4.72e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HRAS—uterine cancer	1.01e-05	4.65e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTEN—uterine cancer	9.98e-06	4.61e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—HRAS—uterine cancer	9.93e-06	4.58e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN1B—uterine cancer	9.89e-06	4.56e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	9.77e-06	4.51e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EP300—uterine cancer	9.52e-06	4.39e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CTNNB1—uterine cancer	9.34e-06	4.31e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—MTHFR—uterine cancer	9.15e-06	4.23e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PTEN—uterine cancer	9.1e-06	4.2e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—MTHFR—uterine cancer	9.07e-06	4.19e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—VEGFA—uterine cancer	9.01e-06	4.16e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NRAS—uterine cancer	8.9e-06	4.11e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—AKT1—uterine cancer	8.89e-06	4.11e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—AKT1—uterine cancer	8.84e-06	4.08e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—AKT1—uterine cancer	8.77e-06	4.05e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EP300—uterine cancer	8.68e-06	4.01e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NRAS—uterine cancer	8.12e-06	3.75e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8e-06	3.69e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—STK11—uterine cancer	7.96e-06	3.68e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP19A1—uterine cancer	7.96e-06	3.68e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KRAS—uterine cancer	7.66e-06	3.54e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PTEN—uterine cancer	7.62e-06	3.52e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—EP300—uterine cancer	7.27e-06	3.36e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CA—uterine cancer	7.04e-06	3.25e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KRAS—uterine cancer	6.99e-06	3.23e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—uterine cancer	6.81e-06	3.14e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HRAS—uterine cancer	6.51e-06	3.01e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CA—uterine cancer	6.42e-06	2.97e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTEN—uterine cancer	6.17e-06	2.85e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—MTHFR—uterine cancer	5.98e-06	2.76e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HRAS—uterine cancer	5.94e-06	2.74e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—EP300—uterine cancer	5.88e-06	2.72e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—AKT1—uterine cancer	5.75e-06	2.66e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CA—uterine cancer	5.38e-06	2.48e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—AKT1—uterine cancer	5.25e-06	2.42e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTEN—uterine cancer	5.09e-06	2.35e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTEN—uterine cancer	5.05e-06	2.33e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—EP300—uterine cancer	4.86e-06	2.24e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—EP300—uterine cancer	4.81e-06	2.22e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—AKT1—uterine cancer	4.39e-06	2.03e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CA—uterine cancer	4.35e-06	2.01e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CA—uterine cancer	3.59e-06	1.66e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CA—uterine cancer	3.56e-06	1.64e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—AKT1—uterine cancer	3.55e-06	1.64e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTEN—uterine cancer	3.33e-06	1.54e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—EP300—uterine cancer	3.18e-06	1.47e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—AKT1—uterine cancer	2.93e-06	1.36e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—AKT1—uterine cancer	2.91e-06	1.34e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CA—uterine cancer	2.35e-06	1.08e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—AKT1—uterine cancer	1.92e-06	8.86e-06	CbGpPWpGaD
